Needham analyst Ami Fadia maintained a Buy rating on Harmony Biosciences Holdings (HRMY – Research Report) today and set a price target of $49.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ami Fadia has given his Buy rating due to a combination of factors related to Harmony Biosciences Holdings’ promising developments and data. The preclinical data for BP1.15205 presented at the SLEEP 2025 conference indicates significant clinical activity in an orexin/ataxin-3 mouse model, with a wide therapeutic index and no safety concerns noted. This data suggests the potential for nearly complete wakefulness at low doses, which is a positive indicator for the drug’s efficacy.
Ami Fadia’s confidence in Harmony Biosciences is further supported by comparative data from other compounds like ORX750 and TAK-861, which demonstrated substantial wakefulness and reduction in cataplexy episodes. The promising results, including a dose-dependent decrease in cataplexy, underscore the potential of Harmony Biosciences’ pipeline to address unmet needs in sleep disorders. These factors collectively justify the Buy rating, reflecting optimism about the company’s future performance and potential market impact.
Fadia covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Blueprint Medicines, and Merus. According to TipRanks, Fadia has an average return of 2.6% and a 46.53% success rate on recommended stocks.
In another report released today, Mizuho Securities also maintained a Buy rating on the stock with a $48.00 price target.